Lyra Therapeutics Inc (NAS:LYRA)
$ 0.2952 -0.0149 (-4.8%) Market Cap: 18.00 Mil Enterprise Value: -31.26 Mil PE Ratio: 0 PB Ratio: 0.23 GF Score: 29/100

Lyra Therapeutics Inc at Jefferies London Healthcare Conference Transcript

Nov 17, 2022 / 04:25PM GMT
Release Date Price: $3.9 (+1.04%)
Chris Howerton
Jefferies LLC - Analyst

My name is Chris Howerton, part of the Jefferies biotechnology research team. I am thrilled to be hosting a fireside chat with Lyra Therapeutics, and on behalf of the company, we have the CEO, Dr. Maria Palasis. So thank you so much for joining us, Maria.

Maria Palasis
Lyra Therapeutics, Inc. - CEO, President

Hi, Chris. It's good to be here in London with you.

Chris Howerton
Jefferies LLC - Analyst

Absolutely. I think this is the first time I've been back in two years. So it's nice to see you in person.

Maria Palasis
Lyra Therapeutics, Inc. - CEO, President

Yeah, yeah.

Questions & Answers

Chris Howerton;Maria Palasis
Jefferies LLC - Analyst;Lyra Therapeutics,

All right. So I guess maybe for those that are not totally oriented to the Lyra story, what could you tell us or how would you describe the lead indication of chronic rhinosinusitis?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot